NL300996I2 - Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout - Google Patents

Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout Download PDF

Info

Publication number
NL300996I2
NL300996I2 NL300996C NL300996C NL300996I2 NL 300996 I2 NL300996 I2 NL 300996I2 NL 300996 C NL300996 C NL 300996C NL 300996 C NL300996 C NL 300996C NL 300996 I2 NL300996 I2 NL 300996I2
Authority
NL
Netherlands
Prior art keywords
naldemedine
solvate
salt
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NL300996C
Other languages
English (en)
Dutch (nl)
Other versions
NL300996I1 (nl
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NL300996I1 publication Critical patent/NL300996I1/nl
Publication of NL300996I2 publication Critical patent/NL300996I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL300996C 2005-05-25 2019-06-26 Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout NL300996I2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2006065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体

Publications (2)

Publication Number Publication Date
NL300996I1 NL300996I1 (nl) 2019-07-03
NL300996I2 true NL300996I2 (nl) 2019-07-30

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300996C NL300996I2 (nl) 2005-05-25 2019-06-26 Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout

Country Status (20)

Country Link
US (4) US8084460B2 (https=)
EP (1) EP1889848B8 (https=)
JP (1) JP4323547B2 (https=)
KR (1) KR100912782B1 (https=)
CN (1) CN101228172B (https=)
AU (1) AU2006250390B2 (https=)
BE (1) BE2019C533I2 (https=)
BR (1) BRPI0610343B8 (https=)
CA (1) CA2609733C (https=)
DK (1) DK1889848T3 (https=)
ES (1) ES2525215T3 (https=)
FR (1) FR19C1042I2 (https=)
HU (1) HUS1900034I1 (https=)
MX (1) MX2007014588A (https=)
NL (1) NL300996I2 (https=)
PL (1) PL1889848T3 (https=)
PT (1) PT1889848E (https=)
RU (1) RU2403255C2 (https=)
TW (1) TWI311056B (https=)
WO (2) WO2006126529A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ[2.2.2]オクタンを有するモルヒナン誘導体およびその医薬用途
JP5827123B2 (ja) * 2008-09-16 2015-12-02 ウェルズ ファーゴ バンク ナショナル アソシエイション 乱用の可能性が低いpeg化オピオイド
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
CN102906099A (zh) * 2010-05-13 2013-01-30 株式会社绿十字 作为神经保护剂的基于(+)-3-羟基吗啡喃的多环衍生物
KR101500915B1 (ko) * 2010-11-12 2015-03-10 시오노기세야쿠 가부시키가이샤 6,7-불포화-7-카르바모일 모르피난 유도체의 결정 및 그의 제조 방법
DK2851075T3 (da) 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
US11135217B2 (en) 2016-12-26 2021-10-05 Shionogi & Co., Ltd. Manufacturing process of formulation having improved content uniformity
EP3773573B1 (en) 2018-04-12 2026-03-18 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
TWI775182B (zh) 2019-10-16 2022-08-21 美商莫菲克醫療股份有限公司 抑制人類整合素αβ
EP4062973A4 (en) 2019-11-20 2023-11-29 Shionogi & Co., Ltd SOLID FORMULATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAND DERIVATIVE
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina
CN121534059A (zh) * 2024-08-09 2026-02-17 盐野义有限公司 一种治疗帕金森综合征或帕金森病的方法和药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
NZ268969A (en) 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
BR9707136A (pt) 1996-01-10 1999-08-31 Smithkline Beecham Spa Derivados morfinóides condesados em heterociclo (ii)
AU5891600A (en) 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
ES2278647T3 (es) * 1999-11-29 2007-08-16 Adolor Corporation Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides.
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
JP2004515455A (ja) 2000-05-05 2004-05-27 ペイン・セラピューティクス・インコーポレイテッド オピオイドアンタゴニスト組成物および投薬形態
EP1280529A2 (en) 2000-05-05 2003-02-05 Pain Therapeutics, Inc. Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
JP4340437B2 (ja) * 2000-10-31 2009-10-07 レンセラール ポリテクニック インスティチュート 8−カルボキサミド−2,6−メタノ−3−ベンズアゾシン
AU2408602A (en) * 2000-11-22 2002-06-03 Toray Industries Indole derivatives and use thereof in medicines
PL368732A1 (en) * 2001-08-23 2005-04-04 Akzo Nobel N.V. C-14 oxidation of morphine derivatives
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
CN1288158C (zh) 2002-07-11 2006-12-06 东丽株式会社 用于预防恶心和呕吐的治疗剂或预防剂
US7164021B2 (en) * 2002-09-18 2007-01-16 The Curators Of The University Of Missouri Opiate analogs selective for the δ-opioid receptor
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
CA2568249C (en) 2004-05-28 2014-12-09 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
KR101500915B1 (ko) 2010-11-12 2015-03-10 시오노기세야쿠 가부시키가이샤 6,7-불포화-7-카르바모일 모르피난 유도체의 결정 및 그의 제조 방법

Also Published As

Publication number Publication date
PT1889848E (pt) 2014-12-09
EP1889848B1 (en) 2014-10-15
ES2525215T3 (es) 2014-12-19
KR20080014791A (ko) 2008-02-14
EP1889848A4 (en) 2011-08-10
USRE46375E1 (en) 2017-04-25
BRPI0610343A2 (pt) 2010-06-15
US20090203723A1 (en) 2009-08-13
NL300996I1 (nl) 2019-07-03
AU2006250390A1 (en) 2006-11-30
FR19C1042I2 (fr) 2020-06-19
JP4323547B2 (ja) 2009-09-02
JPWO2006126637A1 (ja) 2008-12-25
US8084460B2 (en) 2011-12-27
USRE46365E1 (en) 2017-04-11
EP1889848A1 (en) 2008-02-20
US8536192B2 (en) 2013-09-17
CA2609733A1 (en) 2006-11-30
TWI311056B (en) 2009-06-21
AU2006250390B2 (en) 2010-07-08
WO2006126529A1 (ja) 2006-11-30
BRPI0610343B1 (pt) 2020-03-10
WO2006126637A1 (ja) 2006-11-30
TW200726470A (en) 2007-07-16
EP1889848B8 (en) 2014-12-17
HUS1900034I1 (hu) 2019-07-29
KR100912782B1 (ko) 2009-08-18
PL1889848T3 (pl) 2015-04-30
MX2007014588A (es) 2008-01-24
RU2403255C2 (ru) 2010-11-10
CA2609733C (en) 2011-07-19
US20120135978A1 (en) 2012-05-31
FR19C1042I1 (https=) 2019-08-09
BE2019C533I2 (https=) 2025-12-10
DK1889848T3 (en) 2014-12-01
CN101228172A (zh) 2008-07-23
CN101228172B (zh) 2013-04-03
BRPI0610343B8 (pt) 2021-05-25
RU2007148412A (ru) 2009-06-27

Similar Documents

Publication Publication Date Title
NL300996I2 (nl) Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout
NL301261I2 (nl) Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NL301042I2 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I2 (nl) crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301004I2 (nl) Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301020I2 (nl) Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat
FIC20240039I1 (fi) Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
NL300974I2 (nl) Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301104I2 (nl) Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat.
NO2021018I1 (no) kabotegravir eller et farmasøytisk akseptabelt salt eller solvat derav
NL301106I2 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301057I1 (nl) Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL300990I1 (nl) Brigatinib, dan wel een farmaceutisch aanvaardbaar zout daarvan
NL300913I2 (nl) Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
NL300863I2 (nl) Palbociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL300887I2 (nl) Tofacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder tofacitinibcitraat
NL300865I1 (nl) Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
DK1963369T3 (da) Il-21-antagonister
FR2876829B1 (fr) Le tableau anime multisensoriel
ATE386163T1 (de) Gleisbaumaschine
FI20041392A0 (fi) Hitsauslaite
ES1056962Y (es) Maquina para la fabricacion en obra de cunetas de hormigon.